{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:33:58Z","timestamp":1793126038417,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003990","name":"Conseil R\u00e9gional, \u00cele-de-France","doi-asserted-by":"publisher","award":["SESAME 2021"],"award-info":[{"award-number":["SESAME 2021"]}],"id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"Conseil R\u00e9gional, \u00cele-de-France","doi-asserted-by":"publisher","award":["EX061040"],"award-info":[{"award-number":["EX061040"]}],"id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015510","name":"Infrastructures en Biologie Sant\u00e9 et Agronomie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107680","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:13:47Z","timestamp":1791040427000},"page":"107680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of time and temperature on glycation, oxidation, and functional stability of trastuzumab deruxtecan (ENHERTU\u00ae) in dextrose infusion bags"],"prefix":"10.1016","volume":"227","author":[{"given":"Emmanuelle","family":"Hindes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Fourati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Mayssa","family":"Bendiab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Combeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najet","family":"Yagoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-2125","authenticated-orcid":false,"given":"Guillaume","family":"Chevreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Antignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-9423","authenticated-orcid":false,"given":"Hassane","family":"Sadou Yay\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107680_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pharma.2011.07.002","article-title":"Guidelines for the practical stability studies of anticancer drugs: a European consensus conference","volume":"69","author":"Bardin","year":"2011","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.ejps.2026.107680_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107680_bib0003","series-title":"Dynamic Light Scattering: with Applications to Chemistry, Biology, and Physics","author":"Berne","year":"2000"},{"key":"10.1016\/j.ejps.2026.107680_bib0004","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.molimm.2009.02.002","article-title":"Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors","volume":"46","author":"Bertolotti-Ciarlet","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejps.2026.107680_bib0005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.foodchem.2015.07.141","article-title":"Oxygen dependency of one-electron reactions generating ascorbate radicals and hydrogen peroxide from ascorbic acid","volume":"196","author":"Boatright","year":"2016","journal-title":"Food Chem."},{"key":"10.1016\/j.ejps.2026.107680_bib0006","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jps.21530","article-title":"Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality","volume":"98","author":"Carpenter","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ab.2011.04.030","article-title":"Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry","volume":"415","author":"Chevreux","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejps.2026.107680_bib0008","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107680_bib0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1011-1344(01)00208-1","article-title":"Photo-oxidation of proteins and its role in cataractogenesis","volume":"63","author":"Davies","year":"2001","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.ejps.2026.107680_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.31083\/j.fbl2710290","article-title":"A combination of native LC-MS approaches for the comprehensive characterization of the antibody-drug conjugate trastuzumab deruxtecan","volume":"27","author":"Desligni\u00e8re","year":"2022","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejps.2026.107680_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107536","article-title":"Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu\u00ae)","volume":"221","author":"Douez","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2014.04.011","article-title":"Theory and practice of size exclusion chromatography for the analysis of protein aggregates","volume":"101","author":"Fekete","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2026.107680_bib0013","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2026.107680_bib0014","first-page":"42","article-title":"Glycation during storage and administration of monoclonal antibody formulations","volume":"70","author":"Fischer","year":"2008","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik E.V."},{"key":"10.1016\/j.ejps.2026.107680_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4161\/mabs.27876","article-title":"Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes","volume":"6","author":"Haberger","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ejps.2026.107680_bib0016","doi-asserted-by":"crossref","first-page":"19683","DOI":"10.1074\/jbc.REV119.006217","article-title":"Detection, identification, and quantification of oxidative protein modifications","volume":"294","author":"Hawkins","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2026.107680_bib0017","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/10826076.2012.743724","article-title":"Size-Exclusion chromatography for the analysis of protein biotherapeutics and their aggregates","volume":"35","author":"Hong","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.ejps.2026.107680_bib0018","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1074\/mcp.M900540-MCP200","article-title":"Post-translational modifications differentially affect IgG1 conformation and receptor binding","volume":"9","author":"Houde","year":"2010","journal-title":"Mol. Cell. Proteomics MCP"},{"key":"10.1016\/j.ejps.2026.107680_bib0019","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.drudis.2016.04.004","article-title":"Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends","volume":"21","author":"Huang","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107680_bib0025","unstructured":"ICH Q9, 2006."},{"key":"10.1016\/j.ejps.2026.107680_bib0024","unstructured":"ICH Q8 (R2), 2014."},{"key":"10.1016\/j.ejps.2026.107680_bib0020","unstructured":"ICH Q1A(R2), S. testing of new drug substances and drug products, 2003."},{"key":"10.1016\/j.ejps.2026.107680_bib0023","unstructured":"ICH Q6B, S.T.P. and A.C. for B. Products., 1999."},{"key":"10.1016\/j.ejps.2026.107680_bib0022","unstructured":"ICH Q5C, S. testing of biotechnological\/biological products., 1995."},{"key":"10.1016\/j.ejps.2026.107680_bib0021","unstructured":"ICH Q2(R1), V. of analytical procedures: text and methodology., 2005."},{"key":"10.1016\/j.ejps.2026.107680_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/bp040016j","article-title":"Glycosylation of recombinant antibody therapeutics","volume":"21","author":"Jefferis","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ejps.2026.107680_bib0027","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/jps.21746","article-title":"Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization","volume":"98","author":"Ji","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0028","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/jps.23018","article-title":"Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release","volume":"101","author":"Jiskoot","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0029","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.xphs.2024.04.024","article-title":"Evaluating the potential of cyclodextrins in reducing aggregation of antibody\u2013drug conjugates with different payloads","volume":"113","author":"Johann","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.ejps.2026.107680_bib0031","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/bit.260480511","article-title":"Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization","volume":"48","author":"Li","year":"1995","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejps.2026.107680_bib0032","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jasms.2009.08.015","article-title":"Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry","volume":"20","author":"Liu","year":"2009","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ejps.2026.107680_bib0033","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/pharmaceutics17111397","article-title":"Insights into photo degradation and stabilization strategies of antibody-drug conjugates with camptothecin payloads","volume":"17","author":"Luo","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107680_bib0034","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/(SICI)1097-0290(19960820)51:4<458::AID-BIT9>3.0.CO;2-H","article-title":"Effect of high shear on proteins","volume":"51","author":"Maa","year":"1996","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejps.2026.107680_bib0035","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/jps.21566","article-title":"Protein aggregation: pathways, induction factors and analysis","volume":"98","author":"Mahler","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0036","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejps.2026.107680_bib0037","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: a practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejps.2026.107680_bib0038","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejps.2026.107680_bib0039","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","article-title":"Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice","volume":"50","author":"Okamoto","year":"2020","journal-title":"Xenobiotica Fate Foreign Compd. Biol. Syst."},{"key":"10.1016\/j.ejps.2026.107680_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1208\/s12248-026-01247-6","article-title":"In-depth characterization of photo-stressed antibody-drug conjugates by mass spectrometry","volume":"28","author":"Pan","year":"2026","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2026.107680_bib0041","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody conjugation of a chimeric BET degrader enables in vivo activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejps.2026.107680_bib0044","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/bit.21627","article-title":"Non-native protein aggregation kinetics","volume":"98","author":"Roberts","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejps.2026.107680_bib0042","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","article-title":"Therapeutic protein aggregation: mechanisms, design, and control","volume":"32","author":"Roberts","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejps.2026.107680_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.copbio.2014.08.001","article-title":"Protein aggregation and its impact on product quality","volume":"30","author":"Roberts","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejps.2026.107680_bib0045","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.98.3.944","article-title":"Molecular clocks","volume":"98","author":"Robinson","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2026.107680_bib0046","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: An immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2026.107680_bib0048","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11095-020-2763-8","article-title":"Photo-degradation of therapeutic proteins: mechanistic aspects","volume":"37","author":"Sch\u00f6neich","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107680_bib0047","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/BST20250134","article-title":"Mechanistic insight into the oxidative degradation of monoclonal antibodies: relevance to developability and the design of stable pharmaceutical formulations","volume":"54","author":"Sch\u00f6neich","year":"2026","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejps.2026.107680_bib0049","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2026.107680_bib0050","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2026.107680_bib0051","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","article-title":"Dynamic light scattering: a practical guide and applications in biomedical sciences","volume":"8","author":"Stetefeld","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ejps.2026.107680_bib0052","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jchromb.2016.05.045","article-title":"Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies","volume":"1032","author":"Su\u00e1rez","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0053","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107680_bib0054","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/138920108786786402","article-title":"Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods","volume":"9","author":"Vlasak","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejps.2026.107680_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"mAbs"},{"key":"10.1016\/j.ejps.2026.107680_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107680_bib0057","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2018.08.043","article-title":"Protein aggregation \u2013 mechanisms, detection, and control","volume":"550","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107680_bib0058","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2018.08.043","article-title":"Protein aggregation - mechanisms, detection, and control","volume":"550","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107680_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20727","article-title":"Antibody structure, instability, and formulation","volume":"96","author":"Wang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107680_bib0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejps.2026.107680_bib0061","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/mp200548x","article-title":"Protein G, protein A and protein-A-derived peptides inhibit the agitation induced aggregation of IgG","volume":"9","author":"Zhang","year":"2012","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:53:27Z","timestamp":1793123607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872600254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"alternative-id":["S092809872600254X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107680","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of time and temperature on glycation, oxidation, and functional stability of trastuzumab deruxtecan (ENHERTU\u00ae) in dextrose infusion bags","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107680"}}